Human fibrinogen - Guizhou Taibang Biological Products
Latest Information Update: 24 Nov 2015
At a glance
- Originator Guizhou Taibang Biological Products
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Afibrinogenaemia
Most Recent Events
- 24 Nov 2015 Clinical trials in Afibrinogenaemia in China (IV)